ProQR Therapeutics (PRQR) Current Leases (2014 - 2026)

ProQR Therapeutics (PRQR) has reported Current Leases for 10 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.

• Quarterly Current Leases rose 17.6% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 17.6% YoY) and the FY2025 annual result came in at $1.8 million, down 1.4% from the prior year.
• Current Leases climbed to $2.0 million in Q1 2026 per PRQR's latest filing, from $1.8 million in the prior quarter.
• Over the last five years, Current Leases for PRQR reached as high as $2.0 million in Q1 2026 and fell as low as $1.5 million in Q1 2022.
• A 5-year average of $1.7 million and a median of $1.7 million in 2024 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2022 — Current Leases declined 9.58% — and 2024, when it increased 25.56%.
• Year by year, Current Leases stood at $1.6 million in 2022, then gained by 16.37% to $1.8 million in 2023, then declined by 2.91% to $1.8 million in 2024, then slipped by 1.4% to $1.8 million in 2025, then grew by 11.13% to $2.0 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $2.0 million, $1.8 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.